Immunovant(IMVT) - 2026 Q1 - Quarterly Results

Exhibit 99.1 Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025 NEW YORK, August 11, 2025 – Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for the quarter ended June 30, 2025. Recent Highlights and Upcoming Milestones: In June 2025, Immunovant initiated a second potentially registrational trial evaluating IMV ...